GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study$dreal world data of 123 NSCLC patients
Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1(+) is still pending. Here we present the largest real-world data of NSCLC patients harboring ALK/ROS1 rearrangeme...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
27 July 2020
|
| In: |
Lung cancer: targets and therapy
Year: 2020, Volume: 148, Pages: 48-54 |
| ISSN: | 1179-2728 |
| DOI: | 10.1016/j.lungcan.2020.07.022 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.lungcan.2020.07.022 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0169500220305468 
|
| Author Notes: | Nir Peled, Roni Gillis, Saadettin Kilickap, Patrizia Froesch, Sergei Orlov, Elena Filippova, Umut Demirci, Petros Christopoulos, Irfan Cicin, Fatma Bugdayci Basal, Cengiz Yilmaz, Moiseenko Fedor, Taner Korkmaz, Semra Paydas, Oliver Gautschi, Alisan Zirtiloglu, Yesim Eralp, Havva Yesil Cinkir, Ahmet Sezer, Mustafa Erman, Deniz Tural, Hande Turna, Julien Mazieres, Elizabeth Dudnik, Noemi Reguart, David Ross Camidge, Terry L. Ng, Filiz Çay Şenler, İsmail Beypınar, Doğan Yazılıtaş, Ahmet Demirkazık, Aziz Karaoğlu, Kerem Okutur, Hasan Şenol Coşkun, Mehmet Ali Nahit Şendur, Abdurrahman Isikdogan, Devrim Cabuk, Perran Fulden Yumuk, Ibrahim Yıldız, M. Ali Kaplan, Özgür Özyılkan, İlhan Öztop, Omer Fatih Olmez, Kübra Aydin, Adnan Aydıner, Nezih Meydan, Roxana Denisa Grinberg, Laila C. Roisman |
Search Result 1